Evaluation of the efficacy of Er,Cr:YSGG laser in Treating oral benign soft tissue lesions.

BACKGROUND

Managing benign oral soft tissue lesions presents a clinical challenge, often requiring invasive procedures with associated drawbacks. The Er,Cr:YSGG laser has emerged as a potential solution, given its precision and minimal tissue disruption in other medical contexts.

METHODS

This pre-post study involved 16 participants diagnosed with benign oral soft tissue lesions. The lesions were excised using the Er,Cr:YSGG laser (2780 nm) with 2.75‒3.75-W power outputs. Pain was quantified using a numerical rating scale from 0 to 10, and edema presence was noted. Function interference and satisfaction were graded. Healing was assessed via the Early Wound Healing Score (EHS). The observation spanned three postoperative intervals: day 1, day 3, and day 7.

RESULTS

This study included 16 participants with benign oral soft tissue lesions, predominantly pyogenic granuloma and fibroepithelial polyp. Initial discomfort and bleeding were common, while a small proportion reported pain. Er,Cr:YSGG laser treatment significantly reduced discomfort (VAS score) and promoted healing (EHS score) over time. Function interference decreased, and patient satisfaction improved from day 1 to day 7. Additionally, bleeding scores decreased drastically, confirming the laser's effective hemostatic properties.

CONCLUSION

The findings suggest that Er,Cr:YSGG laser treatment presents a promising, less invasive approach for managing oral benign soft tissue lesions, prioritizing patient well-being and contentment alongside successful lesion removal.